NCT01272206View on ClinicalTrials.gov

Investigating Safety and Pharmacokinetics of NNC 0128-0000-2011 Compared to NNC 0128-0000-2021 in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Congenital Bleeding DisorderHaemophilia AHaemophilia B
Interventions
DRUG

NNC 0128-0000-2011

Administered as one single i.v. (intravenous) injection, 100 mcg/kg

DRUG

NNC 0128-0000-2021

Administered as one single i.v. (intravenous) injection, 100 mcg/kg

Trial Locations (1)

M15 6SH

Manchester

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY